Acute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis

Significance: CH is a precursor lesion for lymphoblastic leukemogenesis. ALL with MyM has distinct genetic and clinical characteristics, associated with adverse survival outcomes after chemotherapy. CH can precede ALL years before diagnosis, and ALL with MyM is enriched with activated T cells that respond to immunotherapies such as blinatumomab. See related commentary by Iacobucci, p. 142.

Citing Articles

The dynamic evolution of lineage switch under CD19 CAR-T treatment in non-KMT2A rearranged B-ALL patients.

Qiu S, Mei Y, Gu R, Liu Y, Chen M, Xing H Leukemia. 2024; 39(1):238-242.

PMID: 39482352 DOI: 10.1038/s41375-024-02449-7.

Acute lymphoblastic leukemia in patients treated with lenalidomide for multiple myeloma: a safety meta-analysis of randomized controlled trials combined with a retrospective study of the WHO's pharmacovigilance database.

Morice P, Khalife-Hachem S, Sassier M, Lelong-Boulouard V, Danu A, Pasquier F Blood Cancer J. 2024; 14(1):177.

PMID: 39402057 PMC: 11473840. DOI: 10.1038/s41408-024-01154-z.

Impact of p53-associated acute myeloid leukemia hallmarks on metabolism and the immune environment.

Chomczyk M, Gazzola L, Dash S, Firmanty P, George B, Mohanty V Front Pharmacol. 2024; 15:1409210.

PMID: 39161899 PMC: 11330794. DOI: 10.3389/fphar.2024.1409210.

CHIP: a clonal odyssey of the bone marrow niche.

Schleicher W, Hoag B, De Dominici M, DeGregori J, Pietras E J Clin Invest. 2024; 134(15).

PMID: 39087468 PMC: 11290965. DOI: 10.1172/JCI180068.

"Myeloid" Mutations in ALL Are Not Uncommon: Implications for Etiology and Therapies.

Iacobucci I Blood Cancer Discov. 2024; 5(3):142-145.

PMID: 38689559 PMC: 11061583. DOI: 10.1158/2643-3230.BCD-24-0015.

References

Geyer M, Shaffer B, Bhatnagar B, Mims A, Klein V, Dilip D . Lenalidomide-associated B-cell ALL: clinical and pathologic correlates and sensitivity to lenalidomide withdrawal. Blood Adv. 2023; 7(13):3087-3098. PMC: 10362546. DOI: 10.1182/bloodadvances.2022009212. View

Alaggio R, Amador C, Anagnostopoulos I, Attygalle A, de Oliveira Araujo I, Berti E . The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022; 36(7):1720-1748. PMC: 9214472. DOI: 10.1038/s41375-022-01620-2. View

Steensma D, Bolton K . What to tell your patient with clonal hematopoiesis and why: insights from 2 specialized clinics. Blood. 2020; 136(14):1623-1631. PMC: 7530645. DOI: 10.1182/blood.2019004291. View

Bolton K, Ptashkin R, Gao T, Braunstein L, Devlin S, Kelly D . Cancer therapy shapes the fitness landscape of clonal hematopoiesis. Nat Genet. 2020; 52(11):1219-1226. PMC: 7891089. DOI: 10.1038/s41588-020-00710-0. View

Kimura S, Mullighan C . Molecular markers in ALL: Clinical implications. Best Pract Res Clin Haematol. 2020; 33(3):101193. PMC: 7548398. DOI: 10.1016/j.beha.2020.101193. View

Li J, Dai Y, Lilljebjorn H, Shen S, Cui B, Bai L . Transcriptional landscape of B cell precursor acute lymphoblastic leukemia based on an international study of 1,223 cases. Proc Natl Acad Sci U S A. 2018; 115(50):E11711-E11720. PMC: 6294900. DOI: 10.1073/pnas.1814397115. View

Pourhassan H, Yang D, Afkhami M, Pillai R, Ball B, Al Malki M . High prevalence and inferior long-term outcomes for TP53 mutations in therapy-related acute lymphoblastic leukemia. Am J Hematol. 2022; 97(5):E171-E173. DOI: 10.1002/ajh.26490. View

Richardson P, Jacobus S, Weller E, Hassoun H, Lonial S, Raje N . Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma. N Engl J Med. 2022; 387(2):132-147. PMC: 10040899. DOI: 10.1056/NEJMoa2204925. View

Dobin A, Davis C, Schlesinger F, Drenkow J, Zaleski C, Jha S . STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2012; 29(1):15-21. PMC: 3530905. DOI: 10.1093/bioinformatics/bts635. View

10.

Singhal D, Hahn C, Feurstein S, Wee L, Moma L, Kutyna M . Targeted gene panels identify a high frequency of pathogenic germline variants in patients diagnosed with a hematological malignancy and at least one other independent cancer. Leukemia. 2021; 35(11):3245-3256. DOI: 10.1038/s41375-021-01246-w. View

11.

Bartram J, Patel B, Fielding A . Monitoring MRD in ALL: Methodologies, technical aspects and optimal time points for measurement. Semin Hematol. 2020; 57(3):142-148. DOI: 10.1053/j.seminhematol.2020.06.003. View

12.

Kantarjian H, Stein A, Gokbuget N, Fielding A, Schuh A, Ribera J . Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. N Engl J Med. 2017; 376(9):836-847. PMC: 5881572. DOI: 10.1056/NEJMoa1609783. View

13.

Saygin C, Cannova J, Stock W, Muffly L . Measurable residual disease in acute lymphoblastic leukemia: methods and clinical context in adult patients. Haematologica. 2022; 107(12):2783-2793. PMC: 9713546. DOI: 10.3324/haematol.2022.280638. View

14.

Niroula A, Sekar A, Murakami M, Trinder M, Agrawal M, Wong W . Distinction of lymphoid and myeloid clonal hematopoiesis. Nat Med. 2021; 27(11):1921-1927. PMC: 8621497. DOI: 10.1038/s41591-021-01521-4. View

15.

Miller P, Fell G, Foy B, Scherer A, Gibson C, Sperling A . Clonal hematopoiesis of indeterminate potential and risk of death from COVID-19. Blood. 2022; 140(18):1993-1997. PMC: 9474399. DOI: 10.1182/blood.2022018052. View

16.

Saygin C, Roloff G, Hahn C, Chhetri R, Gill S, Elmariah H . Allogeneic hematopoietic stem cell transplant outcomes in adults with inherited myeloid malignancies. Blood Adv. 2022; 7(4):549-554. PMC: 9979761. DOI: 10.1182/bloodadvances.2022008172. View

17.

Chitadze G, Stengel A, John-Klaua C, Bruckmuller J, Trautmann H, Kotrova M . Somatic TP53 mutations are preleukemic events in acute lymphoblastic leukemia. Blood. 2022; 141(13):1640-1644. PMC: 10651768. DOI: 10.1182/blood.2022017249. View

18.

Stanulla M, Dagdan E, Zaliova M, Moricke A, Palmi C, Cazzaniga G . IKZF1 Defines a New Minimal Residual Disease-Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia. J Clin Oncol. 2018; 36(12):1240-1249. DOI: 10.1200/JCO.2017.74.3617. View

19.

McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A . The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010; 20(9):1297-303. PMC: 2928508. DOI: 10.1101/gr.107524.110. View

20.

Siegel R, Miller K, Fuchs H, Jemal A . Cancer statistics, 2022. CA Cancer J Clin. 2022; 72(1):7-33. DOI: 10.3322/caac.21708. View